Results 121 to 130 of about 4,378 (171)

Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer. [PDF]

Oncol Ther
Mehr S, Hauke R.
europepmc   +1 more source

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. [PDF]

Int J Mol Sci, 2023
Suominen MI, Knuuttila M, Schatz CA, Schlicker A, Vääräniemi J, Sjöholm B, Alhoniemi E, Haendler B, Mumberg D, Käkönen SM, Scholz A.   +10 more
europepmc   +1 more source

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. [PDF]

Future Oncol
Tombal B, Saad F, Gallardo E, Soares A, Loriot Y, McDermott R, Briers E, Lagström M, Coens C, Poncet C, Fournier B, Gillessen S.   +11 more
europepmc   +1 more source

ATM inhibition increases the anti-tumor efficacy of radium-223 (Ra-223) against prostate cancer bone metastasis in preclinical models. [PDF]

JBMR Plus
Lefley DV, Jones CG, Zhou J, Bryant HE, Collis SJ, Down JM, Brown JE, Ottewell PD.   +7 more
europepmc   +1 more source

Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. [PDF]

JNCI Cancer Spectr, 2023
Parker C, Tunariu N, Tovey H, Alonzi R, Blackledge MD, Cook GJR, Chua S, Du Y, Hafeez S, Murray I, Padhani AR, Staffurth J, Tree A, Stidwill H, Finch J, Curcean A, Chatfield P, Perry S, Koh DM, Hall E.   +19 more
europepmc   +1 more source

Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer. [PDF]

Cancers (Basel)
Zang PD, Da Silva DM, Liu ZX, Kandukuri S, Tsao-Wei D, D'Souza A, Kast WM, Pal SK, Kefauver C, Juanqueira M, Yang L, Quinn DI, Dorff TB.   +12 more
europepmc   +1 more source

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. [PDF]

Clin Cancer Res, 2023
Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK.   +10 more
europepmc   +1 more source

Investigation of the safety of Radium-223 chloride in combination with external beam radiotherapy for bone metastases of prostate cancer. [PDF]

J Radiat Res
Makino S, Miyazawa K, Katsuoka Y, Ooe T, Aikawa K, Segawa A, Kobayashi H.   +6 more
europepmc   +1 more source

Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. [PDF]

Prostate Cancer Prostatic Dis
Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR.   +4 more
europepmc   +1 more source

Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models. [PDF]

Int J Mol Sci
Hagemann UB, Schatz CA, Suominen MI, Schlicker A, Knuuttila M, Wilson T, Alhoniemi E, Käkönen SM, Haendler B, Scholz A.   +9 more
europepmc   +1 more source